Discover how CRN04894, a next-generation oral CRF1 receptor antagonist, targets the HPA axis to modulate chronic stress, anxiety, depression, obesity, and cardiometabolic risk with improved selectivity, brain penetration, and safety.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs